Douglas Berger Psychiatrist Tokyo – Contact

The best ways to contact Douglas Berger psychiatrist Tokyo are listed below.

Please read the “Common Topics of Inquiry” section at the bottom of this page to see if these issues pertain to your needs.

※日本語のお問合せフォーム:「日本語送信用紙」をご利用下さい。

Telephone: 03-3716-6624 (+81-3-3716-6624 outside of Japan) for inquiries on counseling and psychotherapy. Long distance/International professional phone consultation by appointment is also available. Please leave a message on the answering machine, most calls will be returned within a few hours, up to 10:45pm, unless requested otherwise. Also, please note that as your call may be forwarded to a mobile phone, you may need to wait a few seconds for transfer, and because of this there is no fax function.

Send E-mail inquiries with the E-mail Submission Form. Please provide your telephone numbers (home, work, and cellular) if you send an e-mail. All inquiries will be replied to promptly. Please call if you do not receive a reply within 2 days, as the server may be down on occasion.

Dr. Douglas Berger psychiatrist Tokyo is located in the Shibuya-Ebisu area of central Tokyo, 5 minutes walk from Yutenji Station, three stops from Shibuya Station on the Toyoko Line (20-minutes direct from Ikebukuro and Saitama on the Fukutoshin line), or 2 stops from Ebisu Station on the Hibiya Subway Line, or 10-minutes by taxi from Ebisu Station which is on the Hibiya Subway Line and the JR Yamanote Line.

  • Therapy Hours: by appointment and include mornings starting at 8:15am until 12:00pm, and evenings from 6:45pm until 11:15pm Monday through Thursday, and mornings 8:15am until 12:00pm on Friday, Saturday, and national holidays.
  • Fees: The Meguro Counseling Center strives to maintain therapy costs as low as possible. Overhead costs are kept to a minimum, and clients are seen as infrequently as optimal care will allow (usually once or twice a month). Please inquire about the current fee structure.

The Yutenji Temple is a 2 minute walk from the Meguro Counseling Center:

Douglas Berger psychiatrist Tokyo - Yutenji Temple
Yutenji Temple – Tokyo

 

Common Topics of Inquiry:

  • Medications in Japan: The Center can not provide specific information in an e-mail on what type of medical care is available in Japan, or how to procure medications that are not available in Japan, out of context to your needs. All persons need to be interviewed in a session in order to recommend an appropriate plan of care after these needs are carefully assessed. These interviews may be conducted by phone or Skype for persons coming from overseas or located outside the Tokyo area. Note that few of the medications used for ADD/ADHD overseas are available in Japan, and some are illegal to have or bring into Japan. The Meguro Counseling Center can discuss the options available for ADD/ADHD treatment in Japan in a scheduled session.
  • Information Requests: Many persons request information for an article, class project, documentary, pharmaceutical marketing, career advice, how to become a counselor, etc. Please note that provision of such information would be a professional service, the exact fees of which would be determined on a case-by-case basis.
  • Hiring Plans & Internships: The Meguro Counseling Center does not currently have an internship program, new hiring plan, or a program for observation/volunteers.
  • How to work as a Psychologist/Counselor in Japan: Click here for inquiries regarding how to work as a clinical psychologist in Japan.
  • Referral Requests: The Meguro Counseling Center can effectively provide Skype or Phone counseling for persons living far from the Tokyo area, but does not have a referral service function for face-to-face counseling in various locations.
  • Inquiries from third parties: We are happy to see persons referred through employers, insurance companies, EAPs, etc., however, the person in question needs send us a mail from our website.

Douglas Berger psychiatrist Tokyo is pleased to try to help you.

Marijuana medicinal products are very different from smoking pot-which cannot be good for psychiatric disorders: https://t.co/Sm1B473teN Author Moss has stock in GW Pharma, makers of marijuana derivative drugs. https://t.co/K6iHnNBhQ1

Some mistakenly think tramadol is a combination drug with both an opioid and an SNRI: https://t.co/kYtNeXyy9x Tramadol has a dual mechanism of action but it is not a combination drug. https://t.co/vhEwPF9JpC

Farah’s book on Hemingway had no interview & he/his estate gave no consent https://t.co/7y5FAs4cvY There's no brain scan/autopsy. Farah does not prove chronic traumatic encephalopathy nor disprove bipolar disorder. The estate may sue after sales grow. https://t.co/1HKbrH9Y6i #li

NIDA instills pot fear in doctors as causing schizophrenia & statements like "use and possession of cannabis is illegal in under federal law" etc: https://t.co/9LKyC7PDrw. Dr. Kosten is NIDA-sponsored & Psychiatric Times known to publish NIDA articles. https://t.co/vhEwPF9JpC #li

Questionable ethics when psychiatrists label persons they did not examine, here deceased poet Robert Lowell: https://t.co/KsJ2H0XRZE Psychiatric conditions are not provable so that (re)labeling Mr. Lowell is concerning even if his doctors did so. https://t.co/RZFx8zOZJO #li

Load More...

ADHD is both over- and under-diagnosed, depending on the set of people you look at: https://t.co/wNPdlFMiUd The authors’ title “Are We Overdiagnosing and Overtreating ADHD?”, is somewhat unfair to the cohort of persons who are underdiagnosed. https://t.co/sJUSXfRv1G

Cold water swimming for depression https://t.co/rBHqTJW7bF What % and which depressives might benefit, is there placebo effect, what temp, duration, frequency is best is still unclear, & if this is reducing inflammation or stress response is conjecture. https://t.co/2opApRuwKL

There is confusion in depression with “full-remission” (no-symptoms), “effective” (defined at each use), and "responsive" (50% improvement) https://t.co/8g5BXeBjET Many trials claim efficacy using "responsive" but "responsive" is easy to achieve. Us: https://t.co/uZEIPRxr0J

Is there a list of CBT clinical trials for anxiety or depressive disorders that have had subject blinding or subject+treater blinding, or blind placebo? Rater blinding (often mistakenly called single-blind) is not so valuable as blind raters just record what the subject reports.

Funding longer GP consults seems ineffective for patients who are dead-set to get antibiotics. Funding public ads campaign, removing prescription repeats, and reducing prescription expiry to between 2 weeks and 3 months as noted in the article seems the way to go.

Load More...